Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease?

Alzheimer Disease and Associated Disorders

Volumn 24, Issue 3, 2010, Pages 278-283

  Koric, Lejla ^a   Felician, Olivier ^a   Guedj, Eric ^a   Hubert, Anne Michele ^b   Mancini, Julien ^c   Boucraut, Jose ^b   Ceccaldi, Mathieu ^a  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Alzheimer disease; atypical; cerebrospinal fluid; posterior cortical atrophy; presenile; primary progressive aphasia; SPECT; tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN;

ADULT; AGING; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; ONSET AGE; PRESENILE DEMENTIA; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BRAIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOASSAY; LOGISTIC MODELS; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 77956405786     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3181d712d9     Document Type: Article

References (55)

1. Letenneur L, Gilleron V, Commenges D, et al. Are sex and educational level independent predictors of dementia and Alzheimer s disease? Incidence data from the PAQUID project. J Neurol Neurosurg Psychiatry. 1999;66:177-183.
2. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer s disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer s Disease. Neurology. 1984;34:939-944.
3. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer s disease: revising the NINCDSADRDA criteria. Lancet Neurol. 2007;6:734-746.
4. Grady CL, Haxby JV, Horwitz B, et al. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J Clin Exp Neuropsychol. 1988;10:576-596.
5. Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991;1:213-216.
6. Linn RT, Wolf PA, Bachman DL, et al. The "preclinical phase" of probable Alzheimer s disease. A 13-year prospective study of the Framingham cohort. Arch Neurol. 1995;52: 485-490.
7. Hodges JR, Patterson K. Is semantic memory consistently impaired early in the course of Alzheimer s disease? Neuroanatomical and diagnostic implications. Neuropsychologia. 1995; 33:441-459.
8. Perry RJ, Hodges JR. Attention and executive deficits in Alzheimer s disease. A critical review. Brain. 1999;122:383-404.
9. Galton CJ, Patterson K, Xuereb JH, et al. Atypical and typical presentations of Alzheimer s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain. 2000;123:484-498.
10. Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer s disease. Brain. 2007;130:2636-2645.
11. Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch Neurol. 1988;45:789-793.
12. Renner JA, Burns JM, Hou CE, et al. Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology. 2004; 63:1175-1180.
13. Tang-Wai DF, Graff-Radford NR, Boeve BF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology. 2004;63:1168-1174.
14. Knibb JA, Xuereb JH, Patterson K, et al. Clinical and pathological characterization of progressive aphasia. Ann Neurol. 2006;59:156-165.
15. Johnson JK, Head E, Kim R, et al. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol. 1999;56:1233-1239.
16. Larner AJ. "Frontal variant Alzheimer s disease": a reappraisal. Clin Neurol Neurosurg. 2006;108:705-708.
17. Frisoni GB, Pievani M, Testa C, et al. The topography of grey matter involvement in early and late onset Alzheimer s disease. Brain. 2007;130:720-730.
18. Mesulam MM, Weintraub S. Spectrum of primary progressive aphasia. Baillieres Clin Neurol. 1992;1:583-609.
19. Poncet M, Felician O, Pellissier JF. Presenile forms of Alzheimer s disease in 2006. In: Jucker M, Beyreuther K, Haass C, et al. eds. Alzheimer s Disease: 100 Year Beyond. Berlin: Springer-Verlag; 2006:115-119.
20. Ceccaldi M, Poncet M, Gambarelli D, et al. Progressive severity of left unilateral apraxia in 2 cases of Alzheimer disease. Rev Neurol (Paris). 1995;151:240-246.
21. Gerstner E, Lazar RM, Keller C, et al. A case of progressive apraxia of speech in pathologically verified Alzheimer disease. Cogn Behav Neurol. 2007;20:15-20.
22. Greene JD, Miles K, Hodges JR. Neuropsychology of memory and SPECT in the diagnosis and staging of dementia of Alzheimer type. J Neurol. 1996;243:175-190.
23. Jagust W, Thisted R, Devous MD, et al. SPECT perfusion imaging in the diagnosis of Alzheimer s disease: a clinicalpathologic study. Neurology. 2001;56:950-956.
24. Talbot PR, Lloyd JJ, Snowden JS, et al. A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia? J Neurol Neurosurg Psychiatry. 1998;64:306-313.
25. Okuda B, Tachibana H, Kawabata K, et al. Comparison of brain perfusion in corticobasal degeneration and Alzheimer s disease. Dement Geriatr Cogn Disord. 2001;12:226-231.
26. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology. 1999;52:1555-1562.
27. Sunderland T, Linker G, Mirza N, et al. Decreased betaamyloid1- 42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289:2094-2103.
28. Bouwman FH, Schoonenboom NS, Verwey NA, et al. CSF biomarker levels in early and late onset Alzheimer s disease. Neurobiol Aging. 2009;30:1895-1901.
29. Van der Vlies AE, Verwey NA, Bouwman FH, et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology. 2009;72:1056-1061.
30. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
31. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
32. Grober E, Buschke H, Crystal H, et al. Screening for dementia by memory testing. Neurology. 1988;38:900-903.
33. Barbeau E, Didic M, Tramoni E, et al. Evaluation of visual recognition memory in MCI patients. Neurology. 2004;62: 1317-1322.
34. Dubois B, Slachevsky A, Litvan I, et al. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55:1621-1626.
35. Deloche G, Hannequin D, Dordain M, et al. Picture confrontation oral naming: performance differences between aphasics and normals. Brain Lang. 1996;53:105-120.
36. Eslinger PJ, Benton AL. Visuoperceptual performances in aging and dementia: clinical and theoretical implications. J Clin Neuropsychol. 1983;5:213-220.
37. Vanderstichele H, De Vreese K, Blennow K, et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO- TAU181P assay for discrimination between Alzheimer s disease and dementia with Lewy bodies. Clin Chem Lab Med. 2006;44:1472-1480.
38. Braak H, Braak E. Neuropathological staging of Alzheimerrelated changes. Acta Neuropathologica (Berl). 1991;82:239-259.
39. Moonis M, Swearer JM, Dayaw MP, et al. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology. 2005;65:323-325.
40. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176-183.
41. Grimmer T, Riemenschneider M, Förstl H, et al. Beta amyloid in Alzheimer s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry. 2009;65:927-934.
42. Tapiola T, PirttiläT, Mikkonen M, et al. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer s disease. Neurosci Lett. 2000;280:119-122.
43. Wagner M, Teichner G, Bachman DL. Diagnostic challenges of using CSF assay of tau and beta-amyloid(42) in atypical degenerative dementias of the Alzheimer type. Arch Clin Neuropsychol. 2003;18:893-903.
44. Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer s disease. Ann Neurol. 1992;42: 631-639.
45. Delacourte A, David JP, Sergeant N, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer s disease. Neurology. 1999;52:1158-1165.
46. Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol. 2009;66:638-645.
47. Tapiola T, Overmyer M, Lehtovirta M, et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer s disease. Neuroreport. 1997;8:3961-3963.
48. Buerger K, Ewers M, PirttiläT, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer s disease. Brain. 2006;129:3035-3041.
49. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid (beta)-amyloid 42 and tau proteins as biomarkers of Alzheimer- type pathologic changes in the brain. Arch Neurol. 2009; 66:382-389.
50. Engelborghs S, Sleegers K, Cras P, et al. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer s disease. Brain. 2007;130:2320-2326.
51. Blennow K, Hampel H. CSF markers for incipient Alzheimer s disease. Lancet Neurol. 2003;2:605-613.
52. Hesse C, Rosengren L, Vanmechelen E, et al. Cerebrospinal fluid markers for Alzheimer s disease evaluated after acute ischemic stroke. J Alzheimers Dis. 2000;2:199-206.
53. Otto M, Wiltfang J, Tumani H, et al. Elevated levels of tauprotein in cerebrospinal fluid of patients with Creutzfeldt- Jakob disease. Neurosci Lett. 1997;225:210-212.
54. Mosconi L, Herholz K, Prohovnik I, et al. Metabolic interaction between ApoE genotype and onset age in Alzheimer s disease: implications for brain reserve. J Neurol Neurosurg Psychiatry. 2005;76:15-23.
55. Filippini N, Rao A, Wetten S, et al. Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer s disease. Neuroimage. 2009;44: 724-728.